Skip to main content
Clinical Trials/NCT02667548
NCT02667548
Unknown
Not Applicable

Prospective Evaluation of Prognosis of Pci Patients Using Network Data in SHengjing Hospital of China Medical University

Shengjing Hospital0 sites7,000 target enrollmentJanuary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Coronary Heart Disease
Sponsor
Shengjing Hospital
Enrollment
7000
Primary Endpoint
Percentage of Participants with Major adverse cardiovascular events (MACE)
Last Updated
8 years ago

Overview

Brief Summary

Coronary heart disease (CHD) has a serious health threaten to population. PCI is a well-proved measure in CHD management. However, the knowledge about the real-life PCI use and how evidence-based therapies in routine clinical practice is limited. By consecutively recruiting PCI patients in a large-scale hospital in in Northeast China,this study will examine various real-life factors, that may affect patients recovery after the procedure. Practical guidelines, appropriateness criteria and quality evaluative system for PCI will be established based on the findings, to improve patients outcomes in future finally.

Detailed Description

Cardiovascular disease (CVD) is a major concern in public health in China. Relatively limited information is available about how evidence-based therapies are incorporated appropriately into routine clinical practice. Practical and applied knowledge from large unselected population is needed to guide practice for quality improvement. This study will enroll patients undergoing PCI in a large-scale hospital in in Northeast China. At study entry, participants will be interviewed during their index hospitalization, to collect information about symptoms, functioning, quality of life, and medical care. Demographic characteristics, medical history, clinical features, diagnostic tests, medications, procedures, and in-hospital outcomes of patients will be abstracted from medical records by well trained professional abstractors. CAG imaging will be reviewed by 2 cardiologists through PACS. Other Procedural data, including stent type, total stent length and so on, came from operation records of PCI cases finished by operators. At 1 month, 6 month, 12 month, 3 year and 5 year after discharge, participants will return to the clinic for follow up visits, a face-to-face interview will be conducted to get information about clinical events, symptoms, functioning, quality of life, and medical care during the recovery period. If participants can not return to the clinic for follow up visits,a telephone interview will be conducted to get the related information. Before discharge,, blood sample will be collected. Participants' blood samples will be stored for future biologic and genetic studies. This study will examine various real-life factors that may affect patients recovery after PCI, including patients' characteristics and treatment measures. Practical guidelines, quality evaluative system, and appropriateness criteria will be established based on the findings, to improve patients outcomes in future finally.

Registry
clinicaltrials.gov
Start Date
January 2016
End Date
January 2021
Last Updated
8 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

YU Tong-tong

attending physician

Shengjing Hospital

Eligibility Criteria

Inclusion Criteria

  • Hospitalized patients undergoing a percutaneous coronary intervention (PCI) for coronary lesions.

Exclusion Criteria

  • Previously enrolled in the R-PUSH study

Outcomes

Primary Outcomes

Percentage of Participants with Major adverse cardiovascular events (MACE)

Time Frame: 5 year

Composite of major adverse cardiovascular events (MACE) including cardiac death, non-fatal AMI, coronary revascularization procedure, or ischemic stroke

Secondary Outcomes

  • Percentage of Participants with all-cause death(5 year)
  • Percentage of Participants with coronary revascularization procedure(5 year)
  • Symptoms status as assessed by SAQ(5 year)
  • Stress as assessed by PSS-4(5 year)
  • Percentage of Participants with cardiac death(5 year)
  • Percentage of Participants with non-fatal AMI(5 year)
  • Percentage of Participants with Cardiac Re-admission(5 year)
  • Percentage of Participants with Adherence to medications for secondary prevention(5 year)
  • Percentage of Participants with ischemic stroke(5 year)
  • Number of Participants who quit smoking(5 year)
  • Quality of life as assessed by EQ-5D(5 year)
  • Depression as assessed by PHQ-8(5 year)

Similar Trials